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Abstract
Background: Microscopic Observation Drug Susceptibility (MODS) and Xpert MTB/Rif (Xpert) are highly sensitive
tests for diagnosis of pulmonary tuberculosis (PTB). This study evaluated the cost effectiveness of utilizing MODS
versus Xpert for diagnosis of active pulmonary TB in HIV infected patients in Uganda.
Methods: A decision analysis model comparing MODS versus Xpert for TB diagnosis was used. Costs were
estimated by measuring and valuing relevant resources required to perform the MODS and Xpert tests. Diagnostic
accuracy data of the tests were obtained from systematic reviews involving HIV infected patients. We calculated
base values for unit costs and varied several assumptions to obtain the range estimates. Cost effectiveness was
expressed as costs per TB patient diagnosed for each of the two diagnostic strategies. Base case analysis was
performed using the base estimates for unit cost and diagnostic accuracy of the tests. Sensitivity analysis was
performed using a range of value estimates for resources, prevalence, number of tests and diagnostic accuracy.
Results: The unit cost of MODS was US$ 6.53 versus US$ 12.41 of Xpert. Consumables accounted for 59 %
(US$ 3.84 of 6.53) of the unit cost for MODS and 84 % (US$10.37 of 12.41) of the unit cost for Xpert. The cost
effectiveness ratio of the algorithm using MODS was US$ 34 per TB patient diagnosed compared to US$ 71 of
the algorithm using Xpert. The algorithm using MODS was more cost-effective compared to the algorithm
using Xpert for a wide range of different values of accuracy, cost and TB prevalence. The cost (threshold value),
where the algorithm using Xpert was optimal over the algorithm using MODS was US$ 5.92.
Conclusions: MODS versus Xpert was more cost-effective for the diagnosis of PTB among HIV patients in our
setting. Efforts to scale-up MODS therefore need to be explored. However, since other non-economic factors
may still favour the use of Xpert, the current cost of the Xpert cartridge still needs to be reduced further by
more than half, in order to make it economically competitive with MODS.
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Background
In most low resource settings where Tuberculosis (TB)
is huge problem, diagnosis conventionally relies on mi-
croscopy. However, TB microscopy has a sensitivity of
only 40–60 % under field conditions, falling to as low as
20 % in the presence of HIV co-infection [1]. Two-thirds
of HIV infected people live in sub-Saharan Africa, and
75 % of the global burden of HIV-associated TB is found
in the region with limited health care resources [2]. With
the launch of the Global Laboratory Initiative, strength-
ening and modernization of TB laboratories in low re-
source settings became a priority for global TB control,
particularly in high HIV prevalence settings [3]. Conse-
quently, since 2007, the array of diagnostics for TB has
expanded tremendously and several of them have been
endorsed by the World Health Organization (WHO) in
such settings [4, 5].
The Xpert MTB/Rif test (Xpert) is an automated rapid
molecular test with high sensitivity for simultaneous
detection of pulmonary TB (PTB) and rifampicin resist-
ance in a one off-test [6].
Xpert relies on real time polymerase chain reaction
(PCR) to amplify a portion of Mycobacteria DNA. The
steps involved in processing the sample, amplification and
detection of the Mycobacterial DNA are automated. This
enables reporting of test results in two-three hours [7].
A number of modelling studies in settings with high
prevalence of TB-HIV co-infection, found Xpert was cost
effective for diagnosis of PTB and reducing mortality in
comparison to microscopy or conventional mycobacterial
culture [8–11]. Thus, the WHO currently recommends
Xpert as the primary diagnostic for HIV-associated TB as
a replacement for TB microscopy [12]. Through the sup-
port of international donors and multilateral development
assistance partners, the Xpert test has been rolled out on a
large scale in several sub-Sahara African countries where
TB and HIV co-infection is prevalent [13, 14]. However,
the rollout of Xpert is faced with affordability and imple-
mentation challenges [15, 16]. There is also emerging evi-
dence currently, that using Xpert in resource limited
health-care settings may not be cost-effective because of
its limited impact on patient mortality [17, 18].
The microscopic observation drug susceptibility (MODS)
assay is an inexpensive test with high sensitivity for diagno-
sis of PTB in HIV infected patients [19], targeted for
resource-limited settings [20, 21]. MODS is a liquid culture
test, for simultaneous detection of TB and resistance to
both rifampicin and isoniazid. MODS relies on two well-
known properties of Mycobacterium tuberculosis (MTB):
First, the rate of growth of TB bacilli in liquid medium is
considerably higher than that on solid medium. Second,
the morphology in liquid culture is characteristic and
recognizable, consisting of so called “cord” like structures.
By using an inverted light microscope to examine culture
plates inoculated with sputum from patients with pre-
sumptive TB, MTB growth can be detected within 7–10
days, for both smear positive and negative samples, com-
pared to conventional solid culture that takes 3–8 weeks
[22, 23]. The MODS test has received increased attention
in recent years and has been improved and standardized
further for more widespread use [24, 25]. However, there
is inadequate information about the full cost of the MODS
procedure, including costs of materials, labour, laboratory
equipment and overhead, which need to be properly
evaluated.
The comparable diagnostic performance of the Xpert
test with MODS and the urgent need of affordable tests
for diagnosis of TB in HIV-infected patients, led us to
perform this study in our setting in Uganda where HIV
and TB are a high burden with an estimated incidence
of 0.51 per 100 person year and 161 per 100,000 popula-
tion respectively [26, 27]. The aim was to compare the
cost-effectiveness of the utilizing the MODS test versus
Xpert as primary tests for diagnosis of pulmonary tubercu-
losis (PTB) among patients infected with HIV. Our results
could be useful for low income settings where implemen-
tation of the tests is planned or is already established.
Methods
Study population
The study population comprised adult HIV-infected pa-
tients older than 18 years, with presumptive active pul-
monary TB. An HIV-infected patient could present with
presumptive PTB regardless of whether they were on anti-
retroviral treatment or not, CD4 count, HIV clinical stage
or history of previous treatment for TB. An HIV patient
was presumed to have active PTB if they had cough for
two or more weeks with or without fever, night sweats,
loss of weight, or blood stained sputum [18].
Study setting
The diagnostic procedures were conducted in a TB re-
search laboratory located within the campus of Mulago
National referral Hospital in Kampala, Uganda. Sputum
specimens were obtained from consecutively presenting
patients to the Mulago Hospital HIV outpatient clinic
and from patients admitted to the medical department
of the hospital. HIV-infected adults presenting with
symptoms and signs of PTB were enrolled on the basis
of the WHO TB screening criteria. Symptomatic patients
provided a spot and morning sputum in a universal sterile
sputum container. At the laboratory, the two samples were
pooled and examined using MODS and Xpert.
Diagnostic procedures
All tests were performed by trained technicians. For the
Xpert MTB/RIF assay, a sample reagent was added to
the pooled sputum sample in a 2:1 ratio. The mixture
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was incubated at room temperature for 15–30 min and
agitated manually. A total of 1 ml of the mixture was in-
troduced into an Xpert MTB/RIF cartridge, which was
then loaded into a GeneXpert instrument, where the
subsequent steps of sample lysis, nucleic acid extraction,
and amplification occurred automatically. The instru-
ment generates the test report automatically within 3 h
which is printed and signed by the technician.
The MODS test was performed in a 24-well tissue
plate. The patient sputum was processed (digestion and
decontamination) with NALC/NAOH 2 % method for
15 min, followed by homogenization. The homogenized
sample was then centrifuged at 3000 X g (Allegra® X-12
series) for 15 min to prepare a sediment. The sediment
was re-suspended with phosphate buffer (pH 6.8) to
make 1–2 ml. The media for the MODS was prepared
with 4.7 g Middlebrook 7H9 broth (Difco, Sparks, MD)
and 2 ml glycerol in 900 ml of distilled water. This
media was autoclaved at 121 °C for 10 min, cooled to
45 °C and enriched with 100 ml of Oleic, Albumin,
Dextrose, catalase (OADC). A portion of the processed
sample (100 μl) and Middlebrook 7H9 broth (800 μl)
and of antibiotic mixture (100 μl) of polymyxin B,
Amphotericin B, Nalidixic acid, Trimethoprim and
Azlocillin (PANTA) were then transferred into wells
giving a final volume of 1 ml/well. Two wells were used
for each processed and quality control sample. For positive
control, 100 μl of a suspension of H37Rv isolate 0.5
McFarland standard, was used. For negative control,
800 μl of Middlebrook 7H9 broth, 100 μl PANTA without
sample was used. The tissue plates were sealed with tape
and ziplock bags and incubated at 37 oC. They were exam-
ined under an inverted light microscope at magnifications
of X10 and X40 for cord formation.
Model structure
A decision-analysis model was constructed using TreeAge
software (version 3.5) to compare the cost effectiveness of
the MODS algorithm to the Xpert algorithm for diagnosis
of TB (Fig. 1). The model involved 10,000 HIV patients
with presumptive PTB. A positive MODS or Xpert test
was either a true positive or a false negative based on the
sensitivity of MODS or Xpert. A negative test was either a
true negative or a false positive based on the specificity of
MODS or Xpert.
Model parameters
The data for diagnostic accuracy in the model were
sourced from systematic reviews of studies on diagnostic
accuracy of Xpert [28] and MODS [19, 20] among HIV
infected patients. We used the pooled values from the
systematic reviews as the base estimates for sensitivity
and specificity of the tests, and the 95 % confidence
interval values as the outer limits for diagnostic accuracy
of the tests (Table 1).
Cost data
Estimates of the costs were made from the provider’s
perspective (Table 2). The costs for the diagnostic pro-
cedure of each test were collected by identifying all the
reagents required to perform the test and their quan-
tities. These were assessed by reviewing the standard op-
erating procedures (SOP) of the tests and observation of
laboratory technicians during performance of the tests
in the research laboratory in Mulago Hospital. We then
computed the cost per test by applying a price per quan-
tity of the resource used for the respective test. Prices of
the reagents, equipment, calibration and training costs
were obtained from laboratory invoices between 2010
Fig. 1 Decision analysis model for diagnosis of pulmonary tuberculosis in HIV patients using MODS or Xpert strategy
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and 2014. All costs were estimated in US$ based 2014
prices. The local costs were converted using the average
exchange rate for 2014 of 2700 Uganda shillings for one
US dollar. In the model we included some sunk costs, e
g water, space and overheads, but since these costs were
the same for the two alternatives, they were automatic-
ally cancelled out in the calculation. We also reviewed
previous studies and guidelines to direct our data collec-
tion [8, 29–32]. We used standard tables of annualization
and a discount rate of 3 % for the capital equipment. We
made the following general assumptions to arrive at the
unit costs for each test: With regard to equipment, the
useful life of the centrifuge, incubator, autoclave, biosafety
hood, inverted microscope were assumed to be 10 years
and 100 % of their use was allocated to the MODS test.
The useful life of a laboratory fridge was assumed to be
10 years and 20 % its use was allocated to the MODS test.
The useful life of the GeneXpert machine was assumed to
be 5 years and 100 % of its use was allocated to the Xpert
test [33]. We used the concessional price of the GeneX-
pert machine and cartridges which is provided to resource
poor settings. The useful life of digital pipettes was as-
sumed to be 3 years and 100 % of their use was allocated
to the MODS test. We assumed that both tests would re-
quire 25 M2 of work space and allocated the cost for space
equally between the two tests. We allocated staff salary
based on the time required to process the MODS test
(2 h) and Xpert test (30 min). We assumed a maximum of
Table 1 Model assumptions for TB diagnosis using MODS or
Xpert
Model input Base value Min-Max Reference
# Test sensitivity Xpert 0.79 0.70–0.86 [6]
# Test specificity Xpert 0.98 0.97–0.99 [6]
# Test sensitivity MODS 0.88 0.86–0.9 [19]
# Test specificity MODS 0.98 0.97–0.99 [19]
# TB prevalence 0.20 0.10–0.30 [49–52]
Table 2 Provider costs involved in the MODS and Xpert diagnostic procedure (US $)
Method
Component MODS Xpert Source
Equipment Xpert test
# Xpert MTB/Rif Machine 4 module and accessories – 19900 Invoice
Equipment MODS test
# Centrifuge (Beckmann Coulter x12R) 18000 – Invoice
# Incubator (CO2) 19500 – Invoice
# Autoclave 24500 – Invoice
# Bio-safety cabinet (class 2) 11500 – Invoice
# Inverted microscope 2700 – Invoice
# Fridge 1300 – Invoice
# Vortex 524 – Invoice
# Pipettes (200ul-1 ml pipette) 218 – Invoice
# Pipettes (50ul-200ul pipette) 218 – Invoice
Consumables
# Xpert cartridge & reagent kit – 10 Invoice
# MODS culture media per year 245 – Invoice
# MODS Culture plate 5 – Invoice
# MODS digestion & decontamination reagents per year 416 – Invoice
Staff
# Annual salary for a laboratory technician 4000 4000 Invoice
# Training costs (5 days for Xpert, 22 for MODS) 990 225 Invoice
Overheads: Utilities, space
# Utilities (water, power, stationary) per year 540 540 Invoice
# Space cost per M2 (25 M2 for either Xpert or MODS) 463 463 Invoice
Quality control
# Xpert calibration cartridge per 2000 tests – 450 Invoice
# MODS proficiency panels per year 940 – Invoice
Walusimbi et al. BMC Health Services Research  (2016) 16:563 Page 4 of 10
20 tests per day for MODS and 16 tests per day for Xpert
and a total of 264 working days per year. We assumed
MODS training required 22 days and Xpert 5 days and a
refresher training for both tests by the laboratory staff
every 3 years.
Model outcomes
The model’s outcome measure were cost per TB patient
diagnosed when the MODS test or the Xpert test were
used for TB diagnosis in HIV infected individuals. We
also derived incremental cost-effectiveness ratios (ICERs),
expressed as US $ per TB patient diagnosed.
Sensitivity analysis
We performed sensitivity analysis of our model based on
adjustments of: (1) the diagnostic accuracy of the MODS
and Xpert tests using the minimum and maximum
values from the systematic reviews, (2) the useful life of
the capital equipment of both tests between five and ten
years, (3) the average number of tests performed per day
between five and twenty, (4) different prices of the re-
agents for MODS and the Xpert cartridge, (5) the per-
centage allocated for shared equipment or staff time, (6)
TB prevalence (10–30 %), corresponding to the most
common values in this patient group from the studies in
the systematic reviews.
Data analysis
Cost data was entered and analyzed in Excel. The cost of
equipment for each test was obtained by dividing the an-
nualized cost of the equipment over the number of tests
performed each year. The cost of consumables for each
test was obtained by the dividing the gross cost of a
given measure of each reagent over the average number
of tests that can performed using that amount. The cost
of quality control (QC) for a MODS test was obtained
by dividing the total costs incurred for QC per year over
the average number of MODS tests that can be performed
each year. The cost of QC for Xpert was obtained by div-
iding the cost of the Xpert calibration cartridge over 2000
tests, which is the number recommended by the manufac-
turer when QC should be performed. Cost-effectiveness
analysis was performed by in-putting the test probabilities
and unit costs into the TreeAge software. A base case ana-
lysis was performed using the pooled estimates for diag-
nostic accuracy of the tests. Sensitivity analysis was
performed by modifying the parameters in the model.
Results
Cost
The average cost for the MODS test was US$ 6.53 com-
pared to US$ 12.41 for the Xpert test. Consumables (re-
agents and chemicals) accounted for 59 % of the cost for
the MODS test while the Xpert cartridge with the reagent
kit accounted for 84 % of the cost for the Xpert test
(Table 3).
The effect of changes in the base-case assumptions on
the unit cost of MODS and Xpert are summarized in
Table 4. In the case of MODS, reducing the useful life of
the capital equipment from ten to five years, increased
the cost of the test moderately to US$ 8.04. Reducing
the number of tests performed each day to five from
twenty increased the cost of the test substantially to US$
11.8. Increasing the price of reagents and chemicals by
two-fold increased cost of the test minimally to US$ 7.8.
Allocating 100 % of all shared equipment and staff time
to MODS increased the cost for the test moderately to
US$ 8.9.
In the case of Xpert, increasing the useful life of the
GeneXpert machine from five to ten years lowered the
cost of the test substantially to US$ 6.5. Reducing the
number of tests performed each day to five from sixteen
lowered the cost of the test minimally to US$ 11.8. Re-
ducing the cartridge price and reagent kit by two-fold
lowered the cost of the test substantially to US$ 7.1. Al-
locating 100 % of staff time to Xpert raised the cost of
the test minimally to US$13.2.
Outcomes and Cost effectiveness
The MODS test generally detected more PTB patients
by 11 % (range 5–23 %) compared to the Xpert test. In
the base-case analysis, involving a cohort of 10,000 HIV
patients with a PTB prevalence of 20 %, the algorithm
using MODS would diagnose 1920 patients compared to
1740 patients by the algorithm using Xpert. The cost-
effectiveness ratio of using MODS was US$ 34 per TB
patient diagnosed compared to US$ 71 when using
Xpert. The algorithm using MODS therefore detected
more patients at lower costs, making it dominant over
the algorithm using Xpert (Table 5).
Sensitivity analysis
In one-way sensitivity analyses, TB prevalence, followed
by the cost of the MODS test had the most influence on
results. The accuracy of the tests had the least influence
(Fig. 2). However, the ratio of the total costs for diagnosis
Table 3 Costs of MODS and Xpert by type of input, (2014$)
Method, (% of total)
Type of input MODS Xpert
Total (US$) 6.53 12.41
# Equipment 1.76, (27) 1.37, (11)
# Consumables 3.84, (59) 10.37, (84)
# Staff (salary and training) 0.46, (07) 0.15, (01)
# Quality control 0.18, (03) 0.23, (02)
# Overheads (utilities and space) 0.29, (04) 0.29, (02)
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of TB patients using either the MODS or Xpert algorithm
remained constant across variable prevalence situations
(Table 6). The dominance of the algorithm using MODS
was persistent across various values of PTB prevalence
and for all the cost values of Xpert between 6.5–13.2 US$.
The threshold value for cost, where using the Xpert algo-
rithm would be optimal over the MODS algorithm was
US $ 5.92.
Discussion
We evaluated the cost-effectiveness of using an algorithm
based on the MODS test versus Xpert test for diagnosis of
Pulmonary Tuberculosis (PTB) in HIV patients from the
perspective of the provider. The MODS algorithm was
dominant over the Xpert algorithm despite adjustments in
test accuracy, cost and TB prevalence.
Prevalence of PTB and the costs of the tests were the
most influential parameters in our findings. However,
while the prevalence of PTB had high influence on the
cost per TB patient detected, it did not change the ratio
of the total costs for the cases detected using either
MODS or Xpert. Thus, in settings where prevalence of
PTB in HIV patients is for example 30 % or more, im-
plementation of the Xpert algorithm could be worthwhile
despite the higher total costs incurred in comparison to
MODS algorithm.
For both tests, the consumables had the most influ-
ence on the unit costs, although variation in the useful
life of equipment and the average number of tests done
each day also had substantial influence on the unit costs.
The threshold for cost in order for Xpert to be optimal
over MODS for diagnosis of PTB in our study popula-
tion was about US$ 6. This value lies within the recom-
mended US$ 4–6 for any new diagnostic to be placed at
the microscopy-center level of the health care system
[34]. This therefore would require further reduction of
the currently subsidized price of the Xpert cartridge by
more than half.
We did not consider data and costs of X-ray in our
study. This is because we focused on new tests (MODS
and Xpert) that provide a definitive (bacteriological)
diagnosis of PTB which is important to ensure correct
TB treatment. Although radiological tests such as X-ray
have an important role in evaluating presumed PTB
patients, their use often results in over diagnosis of
PTB [35, 36]. They are therefore utilized primarily for
diagnosis of extra-pulmonary TB and to assess presumed
PTB patients for other etiologies of respiratory illness. In
regard to cost-effectiveness analysis the costs of X-ray
would cancel out one another since they would be the
same in either the MODS or Xpert diagnostic algorithm.
A recurrent concern limiting the use of MODS is the
total cost of the test arising from infrastructure require-
ments. While it is argued that roll out of Xpert requires
minimal laboratory modifications, the costs involved in
modifying available space to make it suitable for operating
the Xpert test, and the costs for installation of some acces-
sories like power inverters, air conditioners, have limited
its placement at the microscopy-center level [37, 38].
Moreover, we found in our study that equipment and
space accounted just over 30 % of the total cost of the
MODS test. The MODS could therefore be a promising
method for decentralizing sputum culture services up-to
the microscopy-center level of the health care system.
Besides, the test provides a platform for extended drug-
susceptibility testing for drug resistant TB and can be
assembled on site. Therefore, despite the low incidence
of drug resistant TB among newly diagnosed patients
in Uganda [39], MODS would offer rapid diagnosis of
drug-resistant TB in a one-off test. On the other hand,
presumed drug-resistant patients identified using the
Xpert test require confirmation with culture. Thus add-
itional costs are incurred in such situations. Our study
therefore, could have under-estimated the benefits of
implementing MODS in our setting.
Table 4 Effect of changes in the base-case assumptions on the
unit cost of MODS and Xpert, (US $)
Type of test/parameter Effect on cost Increase/
decrease (%)
MODS (base estimate US$ 6.53)
-Reduce useful life of capital equipment
from 10 to 5 years
8.04 +23
-Reduce number of tests to 5 each day 11.8 + 81
-Double price of consumables 7.8 + 19
-Allocate 100 % of shared equipment &
staff time to MODS
8.9 + 36
Xpert (base estimate US$ 12.41)
-Increasing useful life of Xpert from 5
to 10 years
6.5 - 48
-Reduce number of tests to 5 each day 11.8 - 5
-Reduce price of cartridge by half 7.1 - 43
- Allocate 100 % of staff time to Xpert 13.2 + 6
Table 5 Cost-effectiveness of TB diagnosis using MODS or Xpert in a base-case analysis for a cohort of 10,000 HIV presumptive PTB
patients
Strategy Mean cost per test ($) incremental cost per test ($) Cases detected Incremental cases detected Cost effectiveness ICER
MODS 6.53 1920 34 More cost effective
Xpert 12.41 (5.88) 1740 180 71 Dominated
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Even though the MODS was the preferred alternative
in our cost-effectiveness analysis, the Xpert has several
advantages over the MODS test in regard to time to de-
tection, biosafety, level of skills required to operate the
test, labour intensity during performance of the test, and
minimal variation in the test performance and quality
assurance.
The MODS requires a median of seven days to detect
growth in comparison to Xpert that provides results in
3 h allowing for same day detection and treatment.
Xpert therefore has more potential than MODS to avert
patient loss during the process of TB diagnosis. Xpert
also has more potential to avert transmission of disease
arising from early treatment upon detection of TB [40].
Unfortunately, although the turn-around-time of Xpert
is short, in real life settings there is significant delay in
getting the Xpert results and initiating TB treatment
[41, 42] which counters these potential benefits.
Further, current Treatment algorithms suggest that all
patients with positive Xpert results should immediately
start anti-tuberculosis treatment. However, Xpert can
detect DNA from both viable and nonviable TB bacilli.
This presents a challenge that needs to be addressed as
the Xpert test is rolled-out. This is important because
despite the low likelihood of false Xpert positivity among
new TB patients, false Xpert positivity among previously
treated PTB patients may be common. [43, 44]. In such
situations, clinicians may consider awaiting confirmatory
testing using culture tests-which is a major advantage
the MODS offers
A major advantage of utilization of Xpert is the limited
concerns about biosafety during its use. On the other
Fig. 2 One-way sensitivity analysis comparing the influence of model parameters on cost effectiveness of MODS versus Xpert strategy for
diagnosis of pulmonary tuberculosis in HIV patients. The x-axis is the cost per patient diagnosed. Each horizontal bar represents a parameter
varied over the range indicated. Wider bars indicate larger differences in the cost per patient diagnosed by varying the parameter
Table 6 Expected diagnostic yield and costs of MODS versus Xpert strategy across variable prevalence situations for a cohort of
10,000 HIV presumptive PTB patients
Prevalence/Strategy Total TB cases detected Cost per case detected Total cost for cases detected Ratio total cost
TB prevalence (10 %)
MODS 1060 62 65720
Xpert 970 128 124160 1.89
TB prevalence (20 %)
MODS 1920 34 65280
Xpert 1740 71 123540 1.89
TB prevalence (30 %)
MODS 2780 23 63940
Xpert 2510 49 122990 1.92
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hand, biosafety is an important concern with the MODS
and the test has so far therefore, been limited to referral
or research TB culture laboratories. The risks about
utilization of the MODS could however, be addressed by
undertaking the procedures to perform the test inside a
biosafety (Class 2) cabinet and having personal respira-
tory protection for laboratory staff such as N-95 masks.
Further, since the MODS simply involves the inoculation
of a sputum sample into a plate, after which the plate is
sealed within a plastic bag and never again opened, the
biosafety risks of the MODS test could be comparable
to sputum smear microscopy as one study has shown
previously [45].
MODS is more labour intensive and requires more
skilled training to perform in comparison to Xpert. Recent
innovations enabling automated interpretation of the test
could make the labour and skills required to perform the
test comparable to Xpert [46]. This could enable deploy-
ment of the tests to peripheral laboratories even more
feasible. Still, there would be need to standardize the
procedures for the test and set up quality assurance
systems. Currently, the probability of invalid results
from the MODS test requiring repeat testing, is com-
parable to Xpert but could be reduced further through
these measures [38].
Cost-effectiveness analysis is not an evaluation of af-
fordability. Thus the affordability of deploying the MODS
or Xpert in relation to the current and future economic
developments in several of the resource poor settings was
not answered by our study. One study that has evaluated
the cost and affordability of Xpert found that targeted use
of the test would be affordable in the majority of high
burden TB countries [47].
The study also did not compare the epidemiological
and health system effects of using either MODS or Xpert
for diagnosis of HIV associated TB. One study that eval-
uated the population effects of Xpert found that the test
could substantially reduce the TB burden in a resource
limited and HIV prevalent setting [11]. A similar study
involving MODS is required given the dominance of
MODS over Xpert. Based on modelling, MODS could
have similar population effects with Xpert [48]. Our study
assumed only a single diagnostic attempt during the
patient’s disease course with no repeat diagnostic at-
tempts. We also did not explore diagnostic attempts
for multidrug-resistant tuberculosis using either MODS
or Xpert.
Conclusions
The algorithm using MODS was more cost-effective
compared to the algorithm using Xpert for the diagnosis
of TB among HIV patients in our setting. Efforts to
scale-up MODS therefore need to be explored. However,
other non-economic factors may still favour the use of
Xpert in our setting or other similar settings. But the
current cost of the Xpert test, with subsidies, needs to
be reduced further by more than half to make it eco-
nomically competitive with MODS.
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